As a practicing rheumatologist, I have experienced the increasing payer and government involvement shaping our evolving healthcare system. New payment models, changes in health insurance coverage, the federal mandate for the adoption of electronic health records and the implementation of ICD-10 are recent changes that have rocked our world. Our patients are also paying the…
Search results for: biosimilar
Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer
NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of…
German Registry Evaluates Systemic Psoriasis Treatments
The German Psoriasis Registry, PsoBest, found conventional systemic and biologic drugs for psoriasis demonstrated relative safety from serious adverse events in patients between January 2008–December 2012…
ACR 2015: Events to Attend at 2015 ACR/ARHP Annual Meeting
Mark Your Calendars The 2015 ACR/ARHP Annual Meeting in San Francisco is just around the corner, and it’s time to start planning for what is sure to be a busy week! Below are a few events hosted by the government affairs team you don’t want to miss. Legislative Update Sunday, Nov. 8, 9:00–10:00 a.m. In…
Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
In a global Phase 3 trial, subcutaneous secukinumab proved safe and effective in patients with psoriatic arthritis. Also, a version of aspartyl-alanyl diketopiperazine, a biologic for knee OA, has entered Phase 3 trials…
Relapse Rates High in IBD Patients who Stop Treatment
NEW YORK (Reuters Health)—Inflammatory bowel disease (IBD) patients who achieve remission on treatment may want to go off their IBD medications. But half or more of those who do will have a relapse, according to comprehensive analysis of relevant research. “Based on the studies with extended periods of follow up, relapse rates after cessation appear…
Methotrexate Halt Feasible in Some Etanercept RA Responders
NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…
Depression & Anxiety Linked to Poor Rheumatoid Arthritis Outcomes
NEW YORK (Reuters Health)—Rheumatoid arthritis patients with depression and anxiety symptoms may have worse outcomes and poorer response to prednisolone, a secondary analysis of the CARDERA trial has found. “The strength of association between depression/anxiety and disease activity outcomes and treatment response warrants routine screening,” the study’s lead author Faith Matcham at King’s College London…
Guselkumab Studied to Treat RA, Plaque Psoriasis
Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against…
ACR/ARHP Annual Meeting Preview
The meeting with something for everyone! Below is a sneak peek at some of the 2015 ACR/ARHP Annual Meeting’s scientific sessions and content specific to each educational track. Basic Science Track Our knowledge of autoimmunity, bone pathology and other aspects of rheumatic disease is expanding rapidly due to the important research data produced by scientists…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 37
- Next Page »